XNW-5004
- Generic Name
- XNW-5004
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
Phase 1
Recruiting
- Conditions
- Metastatic Castrate-Resistant Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
- Interventions
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Evopoint Biosciences Inc.
- Target Recruit Count
- 307
- Registration Number
- NCT06702995
- Locations
- 🇨🇳
Cancer Hosipital of Shandong First Medical University,440 Jiyan Road, Jinan City, Shandong Province, Jinan, Shandong, China
🇨🇳270 Dongan Road, Shanghai, Shanghai, Shanghai, China
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Phase 1
Recruiting
- Conditions
- CarcinomaUrothelial CarcinomaSquamous Cell Carcinoma of Head and NeckNon-small Cell Lung CancerProstate CancerCervical CancerOther Solid TumorsSmall-cell Lung Cancer
- Interventions
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Evopoint Biosciences Inc.
- Target Recruit Count
- 204
- Registration Number
- NCT06022757
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guodong Province, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath